Open-House Original Discount Agreements 2026-03 - Dolutegravir/Rilpivirin (Active Ingredient Combination)
Original notice title
Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2026-03 - Dolutegravir/Rilpivirin (Wirkstoffkombination)
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No estimated contract value or minimum volume guaranteed; actual revenue dependent on prescriptions.
Contract ends automatically upon patent expiry or loss of market exclusivity before the scheduled end date.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until May 2028
- Pharmaceutical discount agreements for Dolutegravir/Rilpivirin combination.
- Open-House procedure with no negotiation, standard conditions.
Show full summary
Open-House procedure for concluding pharmaceutical discount agreements for Dolutegravir/Rilpivirin combination under §130c SGB V. No estimated value provided. Continuous enrollment possible until 31 May 2028.
Risks
No estimated contract value or minimum volume guaranteed; actual revenue dependent on prescriptions.
Contract ends automatically upon patent expiry or loss of market exclusivity before the scheduled end date.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG.
- Must hold a valid marketing authorization for the medicinal product.
- Must have seat in Germany, EU, or EEA.
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Open-House Original Discount Agreements 2026-03 - Dolutegravir/Rilpivirin (Active Ingredient Combination)
Conclusion of pharmaceutical discount agreements for Dolutegravir/Rilpivirin combination.
Location
Duration
Category
Award Criteria
Deadline
Award details
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130c Abs. 1 SGB V zu Dolutegravir/Rilpivirin (Wirkstoffkombination) im Rahmen eines Open-House-Verfahrens.
Value note
Show original TED data
Original lot title
Open-House-Originale-Rabattverträge 2026-03 - Dolutegravir/Rilpivirin (Wirkstoffkombination)
Original TED description
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130c Abs. 1 SGB V zu Dolutegravir/Rilpivirin (Wirkstoffkombination) im Rahmen eines Open-House-Verfahrens.
Procurement Details
- Publication date
- 23 Apr 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 281148-2026
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Belgium – Pharmaceutical products – Antimycotica
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
France – Pharmaceutical products – 26-10 : ACCORD-CADRE DE FOURNITURE DE MÉDICAMENTS 2026
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No estimated contract value or minimum volume guaranteed; actual revenue dependent on prescriptions.
Contract ends automatically upon patent expiry or loss of market exclusivity before the scheduled end date.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications